Antibody-Based Therapies for Emerging Infectious Diseases
Author Information
Author(s): Arturo Casadevall
Primary Institution: Albert Einstein College of Medicine
Hypothesis
Can antibody-based therapies effectively treat emerging infectious diseases?
Conclusion
Antibody-based therapies have the potential to be effective against newly emergent pathogens, especially in the context of increasing antimicrobial resistance.
Supporting Evidence
- Antibody therapies could be developed against any existing pathogen due to the versatility of antibodies.
- Recent advances in monoclonal antibody production technology allow for the generation of human antibody reagents.
- Antibody-based therapies have shown promise in treating infections caused by pathogens that cannot be cured with existing antimicrobial drugs.
Takeaway
Scientists are looking at using special proteins called antibodies to help fight new germs that make people sick, especially when regular medicines don't work anymore.
Methodology
The article reviews historical and recent advancements in antibody therapies, discussing their effectiveness and challenges.
Limitations
Antibody therapies are often pathogen-specific, which can be a disadvantage in mixed infections, and they can be expensive to develop and administer.
Want to read the original?
Access the complete publication on the publisher's website